Search

Ganulameran

Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949).

Drozitumab

It was developed by Genentech as a drug for the treatment of cancers

SB-269970

In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]

Velafermin

Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated … Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract.

Azvudine

Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

Alaproclate

Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.

UCB7362

It has shown high potency in biochemical (IC₅₀ = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC₅₀ = 10 nM), and _in vivo_ (50 mg/kg dose

LErafAON

Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

Sufugolix

Aloe vera flower

It is not an approved drug.